All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Iopromide Injection for Contrast-Enhanced Mammography

June 26th 2023

The FDA has approved the first and only iodine-based contrast agent iopromide-300, -370 injection for intra-arterial and intravenous contrast-enhanced mammography.

Further Research Needed to Inform the Management of Post-Chemo Residual Nonretroperitoneal Disease in Testicular Cancer

June 26th 2023

Jennifer M. King, MD, expands on the design and methodology of a retrospective study of teratoma in residual nonretroperitoneal disease post-chemotherapy and key findings regarding the correlation between teratoma in the primary tumor and rates of post-chemotherapy teratoma in residual non–nonretroperitoneal disease.

Anti–LAG-3/PD-1 Combination Under Investigation as Adjuvant Therapy in High-Risk Melanoma

June 26th 2023

The combination of fianlimab and cemiplimab represents a wave of novel anti–LAG-3/PD-1 treatments being explored in patients with melanoma at high risk for relapse.

Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

June 25th 2023

Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.

SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

June 24th 2023

The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors plus an aromatase inhibitor followed by fulvestrant.

Sacituzumab Govitecan Approaches EU Approval for Pretreated HR+ Metastatic Breast Cancer

June 23rd 2023

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan-hziy monotherapy in select patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23rd 2023

The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.

Operational Innovations, AI to Play Vital Roles in EOM Data Collection

June 23rd 2023

The arrival of the Enhancing Oncology Model has renewed the uncertainties surrounding value-based care approaches for practices opting into the next wave of Center for Medicare & Medicaid Services performance structure

Four Fox Chase Cancer Center Practitioners Recognized as Top Physicians Under 40 by Pennsylvania Medical Society

June 23rd 2023

The Pennsylvania Medical Society released its list of the 2023 Top Physicians Under 40 award recipients; 4 Fox Chase Cancer Center physicians were honored.

FDA Grants Orphan Drug Designation to ERAS-801 for Malignant Glioma

June 23rd 2023

The FDA has granted an orphan drug designation to the orally bioavailable, reversible small molecule EGFR inhibitor ERAS-801 for the treatment of patients with malignant glioma, including glioblastoma.

NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

June 23rd 2023

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma, including patients with disease progression after transplant or CAR T-cell therapy, and as a category 2A preferred regimen for patients with histologic transformation of indolent lymphoma to DLBCL with no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy.

Carbone Partner Perspectives: Alcohol: The Carcinogen We’re Not Talking About

June 23rd 2023

Despite alarming figures and trends, public awareness of alcohol as a carcinogen remains low.

New and Anticipated Advances Across Hematologic Malignancies Necessitate Improved Navigation of Current Options

June 23rd 2023

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL

June 22nd 2023

Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.

AUTO4 CAR T-Cell Therapy Is Well Tolerated in R/R TRBC1+ Peripheral T-Cell Lymphoma

June 22nd 2023

The CAR T-cell therapy AUTO4 was not associated with dose-limiting toxicities and led to early indications of efficacy in patients with relapsed/refractory TRBC1-positive peripheral T-cell lymphoma.

BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma

June 22nd 2023

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.

Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm

June 22nd 2023

Prithviraj Bose, MD, discusses the development of non-myelosuppressive JAK inhibitors for patients with myelofibrosis, where the future of combination therapy is headed in this population, and the importance of enrolling patients in clinical trials that are tailored to their disease subset and treatment needs.

FDA Issues Complete Response Letter to NDA for ADX-2191 in Primary Vitreoretinal Lymphoma

June 22nd 2023

The FDA has issued a complete response letter to the new drug application seeking the approval of ADX-2191 for the treatment of patients with primary vitreoretinal lymphoma.

UF Health Cancer Center Achieves National Cancer Institute Designation

June 22nd 2023

The University of Florida Health Cancer Center has received prestigious designation from the National Cancer Institute, or NCI, and joins the ranks of the country’s most distinguished cancer centers, becoming the 72nd in the United States and the only one in North Central Florida.

New Strategies for Targeting CTLA-4 Emerge

June 22nd 2023

In 2011, the development of ipilimumab, a novel antibody targeting the CTLA-4 immune checkpoint, helped launch the modern era of anticancer immunotherapy.